Literature DB >> 3085645

Tissue sites of degradation of high density lipoprotein apolipoprotein A-IV in rats.

G M Dallinga-Thie, F M Van 't Hooft, A Van Tol.   

Abstract

The in vivo metabolism of high density lipoprotein (HDL), labeled by incorporation of 125I-apolipoprotein (apo) A-IV, was studied in the rat and compared with the metabolism of HDL labeled with 131I-apo A-I. The 125I-apo A-IV labeled HDL was obtained by adding small amounts of radioiodinated apo A-IV to rat serum, followed by separation of the different lipoprotein fractions by chromatography on 6% agarose columns in order to avoid "stripping" of apolipoproteins by ultracentrifugation. Under both in vitro and in vivo conditions, the 125I-apo A-IV remained an integral component of HDL and was not exchanged to other lipoproteins, including the ""free" apo A-IV fraction. The serum half-life, measured at between 8 and 28 hours after intravenous injection of labeled HDL, was 8.5 +/- 0.5 hours for HDL apo A-IV and 10.2 +/- 0.7 hours for HDL apo A-I. The tissue sites of catabolism of HDL apo A-IV and HDL apo A-I were analyzed in the "leupeptin-model." Only the kidneys and liver showed a significant leupeptin-dependent accumulation of radioactivity. At 4 hours after injection of 125I-apo A-IV/131I-apo A-I labeled HDL, 3.5% +/- 1.0% and 8.4% +/- 2.0% of HDL apo A-IV and 4.6% +/- 1.3% and 2.6% +/- 0.6% of the HDL apo A-I were accumulated in a leupeptin-dependent process in the kidneys and liver, respectively. Immunocytochemical studies revealed that the renal localization of apo A-IV was intracellular and confined to the epithelial cells of the proximal tubuli.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3085645     DOI: 10.1161/01.atv.6.3.277

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  8 in total

1.  Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease.

Authors:  Jan A Krikken; Ron T Gansevoort; Robin P F Dullaart
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

Review 2.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

3.  Plasma proteome dynamics: analysis of lipoproteins and acute phase response proteins with 2H2O metabolic labeling.

Authors:  Ling Li; Belinda Willard; Nadia Rachdaoui; John P Kirwan; Rovshan G Sadygov; William C Stanley; Stephen Previs; Arthur J McCullough; Takhar Kasumov
Journal:  Mol Cell Proteomics       Date:  2012-03-05       Impact factor: 5.911

4.  PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles.

Authors:  Carlos Pérez-Medina; Jun Tang; Dalya Abdel-Atti; Brandon Hogstad; Miriam Merad; Edward A Fisher; Zahi A Fayad; Jason S Lewis; Willem J M Mulder; Thomas Reiner
Journal:  J Nucl Med       Date:  2015-06-25       Impact factor: 10.057

5.  Apolipoprotein A-IV Enhances Fatty Acid Uptake by Adipose Tissues of Male Mice via Sympathetic Activation.

Authors:  Qi Zhu; Jonathan Weng; Minqian Shen; Jace Fish; Zhujun Shen; Karen T Coschigano; W Sean Davidson; Patrick Tso; Haifei Shi; Chunmin C Lo
Journal:  Endocrinology       Date:  2020-04-01       Impact factor: 4.736

6.  Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats.

Authors:  K Fujimoto; K Fukagawa; T Sakata; P Tso
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Renal apolipoproteins in nephrotic rats.

Authors:  H van Goor; M L van der Horst; J Atmosoerodjo; J A Joles; A van Tol; J Grond
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

8.  Higher Free Triiodothyronine Is Associated With Higher HDL Particle Concentration and Smaller HDL Particle Size.

Authors:  Adrian Post; Erwin Garcia; Eke G Gruppen; Daan Kremer; Margery A Connelly; Stephan J L Bakker; Robin P F Dullaart
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.